相关实验视频

Updated: Jul 28, 2025

A Novel Method: Super-selective Adrenal Venous Sampling

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

上腺皮癌中免疫治疗的结果:一个回顾性队列研究

Hanna Remde¹, Laura Schmidt-Pennington², Miriam Reuter¹

¹Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany.

European journal of endocrinology

|June 1, 2023

概括

免疫检查点抑制剂 (ICI) 在现实世界上腺皮癌 (ACC) 治疗中显示出可比的反应和可接受的安全性. 需要进一步的研究来确认PD-L1的存在.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
上皮层癌研究研究

背景情况:

免疫检查点抑制剂 (ICI) 在上腺皮质癌 (ACC) 临床试验中显示出可变的结果.
在先进的ACC中,关于ICI疗效和安全性的现实数据有限.

研究的目的:

在现实生活环境中评估ICI在晚期ACC患者的治疗反应和安全性.
评估客观反应率 (ORR),疾病控制率 (DCR),无进展生存率 (PFS) 和整体生存率 (OS).

主要方法:

在54名晚期ACC患者接受ICI的同情使用下进行的回顾性队列研究.
2016年至2022年间,从6个德国参考中心收集的数据.
分析包括ORR,DCR,PFS,OS,与治疗相关的不良事件 (TRAE) 和编程细胞死亡干1 (PD-L1) 表达.

主要成果:

在52名可评估患者中,ORR为13.5%,DCR为24%.
中位数PFS为3.0个月,中位数OS为10.4个月.
TRAE发生在15名患者身上,与改善的PFS和OS有关. PD-L1阳性与较长的PFS相关. 与pembrolizumab相比,尼沃卢马布的进展和死亡风险较低.

结论:

在ACC中,ICI证明了与其他二线疗法可比的现实反应,在ACC中具有可接受的安全性.
作为响应生物标志物的PD-L1的实用性和尼沃卢马布的潜在益处需要进一步研究.
现实世界的数据支持ICI在先进的ACC中的使用,强调需要个性化治疗策略.

关键词:

在PD-L1中.药物不良反应药物不良反应免疫检查点抑制剂免疫检查点抑制剂米托坦 (mitotane) 是一种有机化合物.治疗治疗治疗治疗治疗治疗

更多相关视频

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

Published on: September 13, 2024

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...